

NanoString Technologies Inc
Form 3
June 25, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Clarus Lifesciences II, L.P.

(Last)

(First)

(Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

06/25/2013

3. Issuer Name and Ticker or Trading Symbol
NanoString Technologies Inc [NSTG]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

___ Director ___X___ 10% Owner
___ Officer ___ Other
(give title below) (specify below)

C/O OF CLARUS VENTURES,
LLC,Â 101 MAIN STREET,
SUITE 1210

(Street)

CAMBRIDGE,Â MAÂ 02142

(City)

(State)

(Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

Date Exercisable

Expiration Date

3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)

Title

Amount or Number of

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Edgar Filing: NanoString Technologies Inc - Form 3

| | | | | Shares | | or Indirect (I) (Instr. 5) | |
|--|-------|------------|-----------------|--------------------------|------|----------------------------------|---|
| Series C Preferred Stock | Â (1) | Â (2) | Common Stock | 2,249,053 (3) (4) (5) | \$ 0 | D | Â |
| Series D Preferred Stock | Â (1) | Â (2) | Common Stock | 812,045 (3) (4) (5) | \$ 0 | D | Â |
| Series D Preferred Warrant (Right to Buy) | Â (1) | 11/01/2018 | Common Stock | 162,408 (3) (4) (5) | \$ 0 | D | Â |
| Series E Preferred Stock | Â (1) | Â (2) | Common Stock | 148,342 (3) (4) (5) | \$ 0 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| Clarus Lifesciences II, L.P. C/O OF CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210 CAMBRIDGE, MA 02142 | Â | Â X | Â | Â |
| Clarus Ventures II GP, L.P. C/O OF CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210 CAMBRIDGE, MA 02142 | Â | Â X | Â | Â |
| Clarus Ventures II, LLC C/O OF CLARUS VENTURES, LLC 101 MAIN STREET, SUITE 1210 CAMBRIDGE, MA 02142 | Â | Â X | Â | Â |

Signatures

| | |
|---|------------|
| /s/ Barbara Mery, Attorney-in-fact | 06/25/2013 |
| __Signature of Reporting Person | Date |
| Barbara Mery, Attorney-in-fact on behalf of Clarus Ventures II GP, L.P. | 06/25/2013 |
| __Signature of Reporting Person | Date |
| Barbara Mary, Attorney-in-fact on behalf of Clarus Ventures II, LLC | 06/25/2013 |
| __Signature of Reporting Person | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects the automatic conversion of each share of Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock into one share of Common Stock to occur upon the closing of the Issuer's initial public offering.

Edgar Filing: NanoString Technologies Inc - Form 3

- (2) Each share has no expiration date.
- (3) Reflects a 1-for-32 reverse stock split of the Issuer's outstanding shares effected June 12, 2013.

Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus Lifesciences II, L.P. ("Clarus"), may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner

- (4) of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of Nicholas Galakatos, a member of the board of directors, and Messrs. Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus.
- (5) Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.